Vibegron is an important therapeutic drug whose efficacy has been verified through clinical trials. However, patients still need to be aware of its potential side effects and medication precautions.

What Are the Side Effects of Vibegron Tablets?

Common Adverse Reactions

Headache: Occurs in approximately 4.0% of patients.

Urinary tract infection: The incidence is relatively high during long-term use (reaching 6.6% in extended studies).

Nasopharyngitis (nasal congestion, sore throat, or runny nose): Approximately 2.8%.

Diarrhea and nausea: Each occurs in approximately 2.2% of patients.

Upper respiratory tract infection: Approximately 2.0%.

Severe Side Effects of Vibegron Tablets That Require Vigilance

Urinary Retention

Vibegron may increase the risk of urinary retention, and close monitoring is particularly necessary for the following patients:

Patients with bladder outlet obstruction: Such patients have a higher risk of dysuria.

Patients concurrently using antimuscarinic drugs: For example, other overactive bladder (OAB) treatment drugs may synergistically increase the probability of urinary retention.

Countermeasures: If symptoms such as dysuria or weak urine flow occur, discontinue the drug immediately and seek medical attention.

Drug Interaction (with Digoxin)

Vibegron can increase the blood concentration of digoxin (Cmax increased by 21%, AUC increased by 11%).

Medication Recommendation: The blood concentration of digoxin should be measured before initiating vibegron treatment.

Conduct regular monitoring during treatment and adjust the dosage of digoxin based on its concentration.

Precautions for Taking Vibegron Tablets

Contraindications

It is contraindicated in patients allergic to vibegron or any component of the preparation.

Administration Method

Standard Usage: Take one 75mg tablet orally once daily, which can be taken on an empty stomach or after meals.

Alternative Option: For patients with swallowing difficulties, the tablet can be crushed and mixed with 15mL of applesauce, taken immediately, followed by drinking water to aid swallowing.

Monitoring Requirements

Patients at high risk of urinary retention: Regularly assess urinary symptoms.

Patients on long-term medication: Pay attention to signs of urinary tract infection (such as painful urination and fever).

Risks in Special Populations

Patients with severe renal impairment (eGFR < 15mL/min) or end-stage renal disease: Contraindicated.

Patients with severe hepatic impairment (Child-Pugh Class C): Contraindicated.

Elderly patients: Although no dosage adjustment is required, attention should be paid to the risk of polypharmacy.

Pregnant and lactating women: Sufficient data are not available; the use should be based on a careful weighing of the benefits and risks.

Storage and Disposal

Store at 20°C–25°C and keep out of reach of children.

Unused drugs to be discarded can be handled through drug take-back programs or household waste disposal.